BioCentury | Aug 22, 2016
Financial News

ProteoMediX completes venture financing

ProteoMediX AG , Zurich, Switzerland Business: Diagnostic Date completed: 2016-08-16 Type: Venture financing Raised: CHF5 million ($5.1 million) Investors: Altos Venture; Zuercher Kantonalbank; existing investors; private investors WIR Staff...
BioCentury | Feb 2, 2015
Financial News

ProteoMediX financial update

...ProteoMediX AG , Zurich, Switzerland Business: Diagnostic Date announced: 2015-01-27 Note: ProteoMediX raised CHF1 million ($1.1...
BioCentury | Apr 14, 2014
Financial News

ProteoMediX completes venture financing

ProteoMediX AG , Zurich, Switzerland Business: Cancer, Diagnostic Date completed: 4/9/14 Type: Venture financing Raised: CHF3.2 million ($3.6 million) Investors: Altos Venture; Zuercher Kantonalbank; existing investors WIR Staff cancer Diagnostic...
BioCentury | Jun 4, 2012
Emerging Company Profile

ProteoMediX: Prostate's PI3K biomarkers

...part because of complications from unneeded biopsies performed as a result of false-positive PSA tests. ProteoMediX...
...four-protein signature: asporin (ASPN), cathepsin D (CTSD), hypoxia up-regulated protein 1 (HYOU1), and olfactomedin-4 (OLFM4). ProteoMediX...
...of the National Academy of Sciences ( see SciBX: Science-Business eXchange, March 3, 2011) . ProteoMediX...
BioCentury | Jan 23, 2012
Financial News

ProteoMediX completes venture financing

ProteoMediX AG , Zurich, Switzerland Business: Cancer, Diagnostic Date completed: 1/19/12 Type: Venture financing Raised: CHF2.6 million ($2.7 million) Investors: Altos Venture; private investors WIR Staff...
BioCentury | Jan 20, 2012
Financial News

ProteoMedix raises $2.7M in series A

...Cancer diagnostic company ProteoMedix AG (Zurich, Switzerland) raised CHF2.6 million ($2.7 million) in a series A round...
...private investors. ProteoMedix is developing a blood-based prostate cancer test that measures five protein biomarkers. ProteoMedix...
BioCentury | Oct 31, 2011
Regulation

Lessons from PSA debate

...a development timeline. Other approaches earlier in development also are intended to augment PSA screening. ProteoMedix AG...
...Ga. Inverness Medical Innovations Inc. (AMEX:IMA), Waltham, Mass. National Institutes of Health (NIH), Bethesda, Md. ProteoMedix AG...
BioCentury | Mar 3, 2011
Cover Story

Prostate's PTEN prognosis

...have separately identified new biochemical signatures that could improve prostate cancer diagnosis and monitoring. 1,2 ProteoMediX AG...
...and compare tests with respect to other, more aggressive cancers," he said. Diagnosing commercial development ProteoMediX...
...can predict PTEN mutation status in other cancer types," said Krek, also a cofounder of ProteoMediX...
BioCentury | Mar 3, 2011
Distillery Techniques

Technology: Markers

...1). SciBX 4(9); doi:10.1038/scibx.2011.269 Published online March 3, 2011 Patent application filed; licensed exclusively to ProteoMediX AG...
Items per page:
1 - 9 of 9
BioCentury | Aug 22, 2016
Financial News

ProteoMediX completes venture financing

ProteoMediX AG , Zurich, Switzerland Business: Diagnostic Date completed: 2016-08-16 Type: Venture financing Raised: CHF5 million ($5.1 million) Investors: Altos Venture; Zuercher Kantonalbank; existing investors; private investors WIR Staff...
BioCentury | Feb 2, 2015
Financial News

ProteoMediX financial update

...ProteoMediX AG , Zurich, Switzerland Business: Diagnostic Date announced: 2015-01-27 Note: ProteoMediX raised CHF1 million ($1.1...
BioCentury | Apr 14, 2014
Financial News

ProteoMediX completes venture financing

ProteoMediX AG , Zurich, Switzerland Business: Cancer, Diagnostic Date completed: 4/9/14 Type: Venture financing Raised: CHF3.2 million ($3.6 million) Investors: Altos Venture; Zuercher Kantonalbank; existing investors WIR Staff cancer Diagnostic...
BioCentury | Jun 4, 2012
Emerging Company Profile

ProteoMediX: Prostate's PI3K biomarkers

...part because of complications from unneeded biopsies performed as a result of false-positive PSA tests. ProteoMediX...
...four-protein signature: asporin (ASPN), cathepsin D (CTSD), hypoxia up-regulated protein 1 (HYOU1), and olfactomedin-4 (OLFM4). ProteoMediX...
...of the National Academy of Sciences ( see SciBX: Science-Business eXchange, March 3, 2011) . ProteoMediX...
BioCentury | Jan 23, 2012
Financial News

ProteoMediX completes venture financing

ProteoMediX AG , Zurich, Switzerland Business: Cancer, Diagnostic Date completed: 1/19/12 Type: Venture financing Raised: CHF2.6 million ($2.7 million) Investors: Altos Venture; private investors WIR Staff...
BioCentury | Jan 20, 2012
Financial News

ProteoMedix raises $2.7M in series A

...Cancer diagnostic company ProteoMedix AG (Zurich, Switzerland) raised CHF2.6 million ($2.7 million) in a series A round...
...private investors. ProteoMedix is developing a blood-based prostate cancer test that measures five protein biomarkers. ProteoMedix...
BioCentury | Oct 31, 2011
Regulation

Lessons from PSA debate

...a development timeline. Other approaches earlier in development also are intended to augment PSA screening. ProteoMedix AG...
...Ga. Inverness Medical Innovations Inc. (AMEX:IMA), Waltham, Mass. National Institutes of Health (NIH), Bethesda, Md. ProteoMedix AG...
BioCentury | Mar 3, 2011
Cover Story

Prostate's PTEN prognosis

...have separately identified new biochemical signatures that could improve prostate cancer diagnosis and monitoring. 1,2 ProteoMediX AG...
...and compare tests with respect to other, more aggressive cancers," he said. Diagnosing commercial development ProteoMediX...
...can predict PTEN mutation status in other cancer types," said Krek, also a cofounder of ProteoMediX...
BioCentury | Mar 3, 2011
Distillery Techniques

Technology: Markers

...1). SciBX 4(9); doi:10.1038/scibx.2011.269 Published online March 3, 2011 Patent application filed; licensed exclusively to ProteoMediX AG...
Items per page:
1 - 9 of 9